5-HT2C receptor involvement in the control of persistence in the Reinforced Spatial Alternation animal model of obsessive–compulsive disorder

Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive–Compulsive Disorder

“…They concluded that mCPP effects were not mediated by 5-HT 2A/C receptors since ritanserin did not block its effects. As in the study by Papakosta et al (22), the data raise the possibility that effects of mCPP are not driven by 5-HT 2C receptors despite data that support a 5-HT 2C mechanism of action of mCPP (24). Nonetheless, neither study provides data to question the hypothesis of the present work and that of Martin et al (19) that 5-HT 2C receptor agonists prevent OCD-like behaviors and do so as a result of interaction with 5-HT 2C receptors.…”

“…In contrast, the conclusion that 5-HT 2C receptor antagonists might be viable OCD treatments was rendered by Papakosta et al (22) from data in a behavioral pharmacology study examining alternation behavior. However, the study did not evaluate 5-HT 2C receptor agonists and, therefore, no data on this mechanism can be gained from their study.…”

The Role of Serotonin in Orbitofrontal Function and Obsessive-Compulsive Disorder

“…Other studies, however, have shown that 5-HT 2A antagonists impair, rather than facilitate, reversal learning (Boulougouris, Glennon, & Robbins, 2008). The 5-HT 2C receptor has also been associated with perseverative behaviors in reversal learning and in other tasks and manipulations proposed to model OCD in animals (Boulougouris et al, 2008;Boulougouris & Robbins, 2010;Flaisher-Grinberg, Klavir, & Joel, 2008;Graf, Kantor, Anheuer, Modos, & Bagdy, 2003;Papakosta et al, 2013).…”

Are 5‐HT3 antagonists effective in obsessive–compulsive disorder? A systematic review of literature

“…The spontaneous alternation behaviour may be differently affected by drugs depending on the substance used to impair it. For example, if impaired alternation is elicited through the 5-HT 1A agonist 8-OH-DPAT, 5-HT 1A inhibitors or long-term downregulators may counteract it, whereas in the mCPP setting, it is 5-HT 2C inhibitors that restore it (Papakosta et al, 2013). Again, all this receptor specificity identified in the laboratory found little correspondence in terms of new drug development and clinical trial application.…”